Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

of improper patient selection and/or improper dosing. FENTORA is contraindicated in the management of acute or postoperative pain including headache/migraine. Life-threatening respiratory depression could occur at any dose in patients not regularly taking around-the-clock opioids. The label for FENTORA is currently being updated to reflect these and other important safety considerations. PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE

IMPORTANT WARNINGS IN THIS LABEL.

FENTORA contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. FENTORA can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing FENTORA in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion. Schedule II opioid substances which include morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest potential for abuse and risk of fatal overdose due to respiratory depression.

FENTORA is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. Because life-threatening respiratory depression could occur at any dose in opioid non-tolerant patients, FENTORA is contraindicated in the management of acute or postoperative pain. This product is not indicated for use in opioid nontolerant patients.

Patients and their caregivers must be instructed that FENTORA contains a medicine in an amount which can b
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2008)... Dec. 5 Genomic Health,...ompany will present results from,four studies at ...m, taking,place December 10-14, 2008, at the Henr...ies analyze Oncotype DX(R), the company,s multi-ge...to predict the likelihood of chemotherapy,benefit...
(Date:12/5/2008)...nd JERSEY CITY, New Jersey, December 5,/PRNewswir...ROSG ), an,innovative molecular diagnostic compan...day its consolidated financial results for the qua...ghts. , The company recorded revenues for t...ues were recorded from the date of acquisition of ...
(Date:12/4/2008)... Medivation, Inc.,(Nasd..., president and chief,executive officer, will be ...l,Markets 2008 Healthcare Conference on Thursday,...attle Against Cancer" from 8:00-8:55 a.m. Eastern ..." from 12:00-12:55 p.m. Eastern, Time, ,...
(Date:12/4/2008)...witzerland, Dec. 4 Octapharma,Cha...is D. Curtin has been,selected to lead Octapharma...,had been Octapharma,s U.S. legal counsel since 20...eutics, Inc. , The largest private plasma p... acquired Life Therapeutics, the Atlanta company t...
Breaking Biology Technology:Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium 2Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium 3Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 2Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 3Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 4Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 5Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 6Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 7Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 8Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 9Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 10Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference 2Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations 2
...d David Batey, Ph.D. , MJ Research, Inc....bstract , We present a real-time quanti... and quantitation of soy genetically modified...osate. The assay utilizes SYBR Green I (SGI) detec...dified organism (GMO) specific sequences as well ,...
...DNA Tissue Kit , Catalog #732-6343, ...affinization , 1. Place 510 mg (0.0050...., tube. Add 300 l xylene and incubate 5 m...ture. , 2. Centrifuge at 13,00016,000 x g ...d the xylene. , 3. Repeat steps 1 and 2 tw...
...ller, Theresa Redila-Flores, Dan Chu, and,Asmita... As the number of diseases and disorders linked t...nning single-base mutations becomes ever more vita...-risk predictor mutations and their , out..., a number of methods , that are faster a...
...*, H.-L. Malinen*, V.-P. Jaakola** and , ...logy Laboratory, REDEC of Kajaani, University of O... ** Department of Biological and Environmental... FIN-40351 Jyvskyl, Finland , , ...#946;LG) is a major whey protein found in the milk...
Other Biology Technology:Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System 2Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System 3Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System 4Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System 5Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System 6Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System 7Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System 8DNA Isolation From 50 to 20 mg of Paraffin-Embedded Tissue 2Temporal Temperature Gradient Electrophoresis: A Powerful Technique to Screen Mutations 2Temporal Temperature Gradient Electrophoresis: A Powerful Technique to Screen Mutations 3Temporal Temperature Gradient Electrophoresis: A Powerful Technique to Screen Mutations 4Temporal Temperature Gradient Electrophoresis: A Powerful Technique to Screen Mutations 5Temporal Temperature Gradient Electrophoresis: A Powerful Technique to Screen Mutations 6Temporal Temperature Gradient Electrophoresis: A Powerful Technique to Screen Mutations 7Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 2Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 3Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 4Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 5Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 6Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 7Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 8Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 9Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 10Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 11Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing 12
(Date:12/5/2008)...ne fifth of the standard dose of a commonly used m... full dose. This new finding should allow scarce v...ly during epidemics in Africa. , In a study init... together with Epicentre (the research arm of Doct...barara University of Science and Technology in Uga...
(Date:12/5/2008)...he Stowers Institute,s Baumann Lab has discovered ...omerase, the enzyme that replenishes the sequences...division. The findings were published today in the...merase is viewed as a promising cancer treatment t...cer cells. In order to identify small molecules th...
(Date:12/5/2008)...ASHINGTON, DCOn Tuesday, November 25, 2008, the O...enter gathered experts from many disciplines to sh...promise of prevention and intervention strategies ...f Columbia and nationwide. , Through the Obesity...ildhood obesity using a multidisciplinary approach...
(Date:12/4/2008)... New Rochelle, NY, December 4, 2008Researchers ar...inase (PI3-kinase) pathway as studies continue to ...suppresses tumor growth, reports Genetic Engineer...involved in angiogenesis, cell growth, differentia... PI3/AKT/mTOR pathway, which plays a key role in c...
Breaking Biology News(10 mins):Stowers Institute's Baumann Lab identifies key step in maturation pathway of telomerase 2Children's National convenes first childhood obesity symposium 2Children's National convenes first childhood obesity symposium 3Children's National convenes first childhood obesity symposium 4Bright Starts 28TM 29 Adds New Twist to Old Favorites 23441 1Bright Starts 28TM 29 Adds New Twist to Old Favorites 23441 2Bright Starts 28TM 29 Adds New Twist to Old Favorites 23441 3The Henry H Kessler Foundation Appoints New Vice President for Research and Strengthens Relationship With Current Research Luminary 23436 1The Henry H Kessler Foundation Appoints New Vice President for Research and Strengthens Relationship With Current Research Luminary 23436 2FDA Approves EOVIST 28R 29 to Detect and Characterize Focal Liver Lesions 6412 1FDA Approves EOVIST 28R 29 to Detect and Characterize Focal Liver Lesions 6412 2FDA Approves EOVIST 28R 29 to Detect and Characterize Focal Liver Lesions 6412 3FDA Approves EOVIST 28R 29 to Detect and Characterize Focal Liver Lesions 6412 4FDA Approves EOVIST 28R 29 to Detect and Characterize Focal Liver Lesions 6412 5FDA Approves EOVIST 28R 29 to Detect and Characterize Focal Liver Lesions 6412 6FDA Approves EOVIST 28R 29 to Detect and Characterize Focal Liver Lesions 6412 7MIGENIX Corporate Update and Requisition of Special Meeting 6407 1MIGENIX Corporate Update and Requisition of Special Meeting 6407 2MIGENIX Corporate Update and Requisition of Special Meeting 6407 3MIGENIX Corporate Update and Requisition of Special Meeting 6407 4MIGENIX Corporate Update and Requisition of Special Meeting 6407 5MIGENIX Corporate Update and Requisition of Special Meeting 6407 6MIGENIX Corporate Update and Requisition of Special Meeting 6407 7MIGENIX Corporate Update and Requisition of Special Meeting 6407 8
... is a characteristic of diverse species of birds, ... what circumstances it proves useful have remained...that strongly suggest that for some birds head bob...sual world, despite the motion of their bodies, an...s such as food items. , The motion associated with...
...or human exercise? According an article published ...ake,s eating habits make it a prime model of cardi...ty to adapt to altered physiological requirements,...snake may provide insights into how remodeling of ... and in response to some diseases. , The python do...
...nic stem cell lines specifically tailored to match...es of various ages, suffering from disease or spin...by the journal Science, which is published by AAAS...xpress website on 19 May, 2005. , These cell lines...n the laboratory. The work also moves scientists o...
...xed blessings for scientists who follow research i...onducted by scientists from Cincinnati Children,s ...ol and Hamburg University in Germany, reveals impo...forming stem cells regenerate. On the other hand, ...fects associated with genetic engineering of stem ...
Other Biology News:Bobbing birds do it for a reason 2Scientists generate patient-specific stem cells, Science study says 2Scientists generate patient-specific stem cells, Science study says 3Scientists generate patient-specific stem cells, Science study says 4Science study holds implications for gene therapy and stem cell biology 2Science study holds implications for gene therapy and stem cell biology 3
Zymoclean Gel DNA Recovery Kit from Zymo Research
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form.
DeadEnd Fluorometric TUNEL System from Promega
Agarose overlays are commonly used in baculovirus plaque assays. Many commercial "DNA grade" agaroses either contain contaminants that are toxic to insect cells or lack the physical characteristics r
Biology Products: